REFERENCES
1. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154:1121-201.
2. Chen LY, Chung MK, Allen LA, et al.; American Heart Association Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Quality of Care and Outcomes Research, and Stroke Council. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. Circulation. 2018;137:e623-44.
3. Joglar JA, Chung MK, Armbruster AL, et al.; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1-e156.
4. Rosman L, Wang K, Sarkar S, Ziegler PD, Passman RS. Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction. Eur Heart J. ;2026:ehag203.
5. Charitos EI, Stierle U, Ziegler PD, et al. A comprehensive evaluation of rhythm monitoring strategies for the detection of atrial fibrillation recurrence: insights from 647 continuously monitored patients and implications for monitoring after therapeutic interventions. Circulation. 2012;126:806-14.
6. Kamel H, Okin PM, Longstreth WT Jr, Elkind MS, Soliman EZ. Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation. Future Cardiol. 2015;11:323-31.
7. Bertelsen L, Diederichsen SZ, Haugan KJ, et al. Left atrial late gadolinium enhancement is associated with incident atrial fibrillation as detected by continuous monitoring with implantable loop recorders. JACC Cardiovasc Imaging. 2020;13:1690-700.
